Addressing the challenges that affect COVID-19 prevention in the rural areas of Abia State, Nigeria

Authors

  • E. E. Enwereji Department of Public Health, Abia State University, Uturu, Abia State, Nigeria
  • M. C. Ezeama Department of Public Health, Abia State University, Uturu, Abia State, Nigeria

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20204345

Keywords:

COVID-19, Prevention, Rural areas, Partnership, Opinion

Abstract

Background: Using directives have been the standard approach of changing public behavior. But studies have shown that directives fail because people hate being told what to do. Telling individuals to use limited resources and other social amenities in rural areas to prevent coronavirus disease 2019 (COVID-19) infection may lead to skepticism in practice of public health recommendations on COVID-19 prevention. Even non-availability of basic hand washing facilities (soap and clean water) which form fundamental mechanism to prevent COVID-19 can expose people to infection. Study assesses factors and conditions that influence the practice of Center for disease control (CDC) preventive measures against COVID-19 in rural areas.

Methods: This is a qualitative study that utilized information from 36 health care professionals under the aegis of committee for COVID-19 prevention. These committee members are working together in partnership with state government to provide services to control, prevent and cushion effects of COVID-19 pandemic.

Results: Findings from 36 health care professionals made up of 10 (27.8%) females and 26 (72.2%) males showed that factors such as denial of existence of the virus, labeling virus as only urban limited, poor knowledge of mode of transmission, terming virus as ploy politicians use to siphon resources meant for rural development contributed to non-observation of CDC guidelines for COVID-19 prevention.

Conclusions: Denying existence of COVID-19 and not observing CDC guidelines will increase community transmission thereby, expose people in communities to infection. Therefore, education is needed to enlighten people in communities on benefits of observing CDC guidelines.

Author Biographies

E. E. Enwereji, Department of Public Health, Abia State University, Uturu, Abia State, Nigeria

Department of Public Health, lecturer

M. C. Ezeama, Department of Public Health, Abia State University, Uturu, Abia State, Nigeria

PUBLIC hEALTH

References

Mejia B. With masks at the ready, ICE agents make arrests on first day of California coronavirus lockdown. Los Angeles Times. March 17, 2020. Available at: https://www.latimes.com/california/story/2020-03-17/for-ice-agents-its-business-as-unusual-day-after-sweeping-coronavirus-order. Accessed on 5 April 2020.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-3.

Wang J, Yuan B, Li Z, Wang Z. Evaluation of public health emergency management in China: a systematic review. Int J Environ Res Public Health. 2019;16(18):3478.

Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019;11(1):41.

Mendenhall E. Syndemics: health in context. Lancet. 2017;389(10072):881.

Nathaniel S. Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters Am J Public Health. 2020;110(5):648-9.

Lourenco J, Paton R, Ghafari M. Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. 2020. Available at: https://www.medrxiv.org/content/10.1101/2020.03.24.20042291v1.article-info. Last accessed on April 8, 2020.

Backer, JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5):2000062.

Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digital Health. 2020;2:201-8.

World Health Organization (WHO), “Novel Coronavirus – China” (WHO, 2020); www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/. Accessed on 8 April 2020.

The Center for Systems Science and Engineering at Johns Hopkins University, Coronavirus COVID-19 Global Cases (2020); www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed on 8 April 2020.

WHO. Coronavirus disease 2019 (COVID-19): Situation Report- 43. 2020. www.who.int/docs/default-source/coronaviruse/situation-reports/20200303-sitrep-43-covid-19.pdf?sfvrsn=2c21c09c_2. Accessed on 8 April 2020.

Abhjieet Pandey, Ajinkya Nitin Nikam, Ajjappla Basavaraj Shreya, et al. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sciences. 2020;256:117883.

Scott B. Halstead, Ramesh Akkina. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. Frontiers in Immunology. 2020;11:1196.

Alexis Mathian, Zahir Amoura. Response to: Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour et al. Annals of the Rheumatic Diseases. 2020;2020:217875.

Amin N. Olaimat, Iman Aolymat, Hafiz M. Shahbaz, et al. Knowledge and Information Sources About COVID-19 Among University Students in Jordan: A Cross-Sectional Study. Frontiers in Public Health. 2020;8.

Alanagreh L, Alzoughool F, Atoum M. Risk of using hydroxychloroquine as a treatment of COVID-19. International Journal of Risk & Safety in Medicine. 2020;31(3):111-6.

Jeschke KN, Bonnesen B, Hansen EF. Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. European Clinical Respiratory Journal. 2020;7(1):1761677.

Uddin M, Mustafa F, Rizvi TA. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses. 2020;12(5):526.

Halstead SB. An Urgent Need for “Common Cold Units” to Study COVID-19. American Journal of Tropical Medicine and Hygiene. 2020;102(6):1152.

Abena PM, Decloedt EH, Bottieau E. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. American Journal of Tropical Medicine and Hygiene. 2020;102(6):1184.

Gopinathannair R, Merchant FM, Lakkireddy DR. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. Journal of Interventional Cardiac Electrophysiology. 2020;3:1-8.

TripathyJP. Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID‐19 in India? Journal of Medical Virology. 2020;92(9):1391-3.

Orlandi M, Lepri G, Bruni C. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clinical Rheumatology. 2020; 39(7):2043-7.

Ryan GA, Purandare NC, McAuliffe FM. Clinical update on COVID ‐19 in pregnancy: A review article. Journal of Obstetrics and Gynaecology Research. 2020;46(8):1235-45.

Sharma A, Tiwari S, Deb MK. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies. International Journal of Antimicrobial Agents. 2020; 106054.

Scalise M, Indiveri C. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19. SLAS Discovery. 2020;247255522093442.

Campos, Oliveira DMO, Andrade CBS, JMA. Fighting COVID-19. Brazilian Journal of Biology. 2020;80(3):698-701.

Santillán-García A, Bravo-Jeria R, Verdugo-Paiva F. Living evidence in response to controversies about the use of antimalarials in COVID-19. Revista Espanola de Cardiologia. 2020;73(8):693-4.

Lu CC, Chen MY, Lee WS. Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association. 2020;l83(6):534.

Abrams-Downey A, Saabiye J, Vidaurrazaga M. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. European Urology Focus. 2020;6(5):1028-31.

Fink S. Worst-case estimates for US coronavirus deaths. New York Times. 2020. Available at: https://www.nytimes.com/2020/03/13/us/coronavirus-deaths-estimate.html. Accessed on 29 March 2020.

Brinkley-Rubinstein L, Cloud DH. Mass incarceration as a social-structural driver of health inequalities: a supplement to AJPH. Am J Public Health. 2020;110(1):14-5.

Hunter DJ. COVID-19 and the stiff upper lip—the pandemic response in the United Kingdom. N Engl J Med. 2020;382(16):e31.

Ferguson NM. Imperial College of Science, Technology and Medicine. Impact of Non-Pharmaceutical Interventions (NPIs) to Reduce COVID19 Mortality and Healthcare Demand. London: Imperial College COVID-19 Response Team. 2020.

Lipsitch M. Far more people in the US have the coronavirus than you think. Washington Post. March 23, 2020. Available at: https://www.theeagle.com/opinion/columnists/far-more-people-in-the-u-s-have-thecoronavirus/article_

acb63-0299-50ec-a142-06d9ba32042a.html. Accessed on 8 April 2020.

Downloads

Published

2020-09-25

How to Cite

Enwereji, E. E., & Ezeama, M. C. (2020). Addressing the challenges that affect COVID-19 prevention in the rural areas of Abia State, Nigeria. International Journal Of Community Medicine And Public Health, 7(10), 3824–3829. https://doi.org/10.18203/2394-6040.ijcmph20204345

Issue

Section

Original Research Articles